Doxorubicin Hydrochloride
Product Images NDC 16714-742

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 16714-742). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20mgcarton (20mgcarton)

Packaging label for Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) single-dose vial by NorthStar RxLLC. Label includes dosing strength, administration route (intravenous infusion only), storage instructions (refrigerate 2° to 8°C, do not freeze), and a warning stating liposomal formulation is not a substitute for doxorubicin HCl. Manufacturer and product origin details are shown with barcodes.*

FDA Label Image

20mgvial (20mgvial)

Label for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) single-dose vial for intravenous infusion. Highlights liposomal formulation and specifies it is not substitutable for doxorubicin HCl. Label includes storage instructions, dilution note, manufacturer NorthStar Rx LLC in Memphis, TN, and Nacto Pharma Ltd. in India.*

FDA Label Image

50mgcarton (50mgcarton)

Packaging label for Doxorubicin Hydrochloride Liposome Injection 50 mg/25 mL (2 mg/mL) by NorthStar RxLLC. The label indicates a single-dose vial for intravenous infusion only, with storage instructions to refrigerate at 2° to 8°C and not freeze. It includes a warning that the liposomal formulation should not be substituted for doxorubicin HCl, and instructions that the vial must be diluted prior to administration.*

FDA Label Image

50mgvial (50mgvial)

Doxorubicin Hydrochloride Liposome Injection 50 mg/25 mL (2 mg/mL) vial label from NorthStar RxLLC. This liposomal formulation is indicated for intravenous infusion only and is not a substitute for doxorubicin HCl. The label includes refrigeration instructions, caution as a cytotoxic agent, and directions to see package insert for dosing.*

FDA Label Image

Hspc (Hspc)

Chemical structure diagram of the active ingredient Doxorubicin Hydrochloride, showing the molecular arrangement including various carbon, hydrogen, oxygen, nitrogen, and phosphorus atoms with functional groups and bonds.*

FDA Label Image

Mpeg (Mpeg)

Chemical structure diagram depicting a complex organic molecule with multiple functional groups, including ester, amide, phosphate, and long hydrocarbon chains. This structure is related to Doxorubicin Hydrochloride as provided by the product data.*

FDA Label Image

Peglyated (Peglyated)

Illustration of a liposome-based drug delivery system for Doxorubicin Hydrochloride. The diagram shows an aqueous core containing entrapped doxorubicin HCl, surrounded by a liposomal bilayer, and an outer MPEG-DSPE coating.*

FDA Label Image

Graph (Graph)

A Kaplan-Meier survival curve chart comparing progression-free survival over time (months) between two groups: one treated with Doxorubicin Hydrochloride plus Bortezomib, and the other with Bortezomib alone. The y-axis shows the percent of subjects progression-free, and the x-axis represents time in months. The chart includes censored data points and a table of subjects at risk over time. Statistical data includes a p-value less than 0.0001 and a hazard ratio with confidence interval.*

FDA Label Image

Structure (Structure)

Chemical structure of Doxorubicin Hydrochloride, showing the detailed molecular arrangement including multiple hydroxyl groups, ketones, and an aminosugar moiety bound to the anthracycline core.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.